



# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

NASDAQ: **IDYA**

August 2024

## IDEAYA Highlights

**Breakthrough Science** on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

**Broad Pipeline** of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

**Proven Management Team** with deep business and scientific experience has built leading oncology companies

**Pharma Strategic Partnerships** include combinations with Pfizer<sup>1</sup>, Amgen<sup>1</sup>, Gilead<sup>1</sup>, Merck<sup>1</sup>, and GSK partnership with ~\$2 billion<sup>2</sup> in potential milestones

**Strong Balance Sheet** of ~\$1.2 billion<sup>3</sup> with capital efficient model

**Analyst Coverage** by BTIG, Capital One, Citi, Goldman Sachs, Jefferies, JP Morgan, Leerink, LifeSci Capital, Mizuho Securities, Oppenheimer, RBC, Stifel and Wedbush

- (1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), Amgen (IDE397 + AMG193), Gilead (IDE397 + Trodelvy®), and Merck (IDE161 + KEYTRUDA®); IDEAYA retains all commercial rights to its products
- (2) GSK Collaboration, Option and License Agreement
- (3) Includes aggregate of \$952.7M cash, cash equivalents and marketable securities as of June 30, 2024, plus pro forma \$283.8M estimated net proceeds from July 2024 public offering

# IDEAYA Biosciences – Fact Sheet

**Founded 2015** on the thesis that Synthetic Lethality would emerge as a central focus of precision medicine oncology, with significant Pharma interest and the potential to develop *first-in-class* therapeutics for biomarker-defined cancer patient populations.

**Broad Pipeline** of clinical and preclinical precision medicine oncology programs with defined patient biomarkers, including

- *Darovasertib (IDE196)* targeting PKC in combination with crizotinib, a cMET inhibitor, for metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma, and as monotherapy for neoadjuvant and adjuvant uveal melanoma (UM),
- *IDE397* targeting MAT2A for patients having tumors with MTAP deletion, a population estimated to represent ~15% of all solid tumors,
- *IDE161* targeting PARG for patients having solid tumors with HRD and endometrial cancer,
- *Pol Theta* for patients with tumors having mutations in BRCA or other homologous recombination deficiency (HRD),
- *Werner Helicase* for patients having tumors with high microsatellite instability,
- *Next-Gen SL*, for MTAP and KAT6 pathway and undisclosed synthetic lethality targets for molecularly-defined patient populations, and
- *B7H3/PTK7 Bi-Specific ADC* for patients with B7H3+/PTK7+ expression in their tumors.

**Proven Management Team** with deep business and scientific experience has built leading oncology biotech companies, led by CEO Yujiro S. Hata, M.B.A., an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

**Scientific Advisory Board** includes world-class scientists who are key opinion leaders in precision medicine oncology and synthetic lethality, including SAB Chair Frank McCormick, Ph.D. (UCSF), and Bill Sellers, M.D. (Broad Institute, Novartis).

**Pharma Strategic Partnerships and Collaborations** with Pfizer<sup>1</sup>, Amgen<sup>1</sup>, Gilead<sup>1</sup>, Merck<sup>1</sup>, and GlaxoSmithKline<sup>2</sup>. The GSK strategic partnership validates IDEAYA's Synthetic Lethality platform and enhances the companies' collective leadership in Synthetic Lethality. IDEAYA and GSK are collaborating on two programs – *Pol Theta* and *Werner Helicase*. IDEAYA retains commercial rights of 50% US profit-share and ex-US royalties for *Werner Helicase*, and worldwide royalties for *Pol Theta*, with potential to earn up to approximately \$2 billion in aggregate cash milestones across the two programs.

**Strong Balance Sheet** of ~\$1.2 billion<sup>3</sup>, with a capital efficient model, supporting clinical data milestones across multiple programs, including for darovasertib – targeting PKC in metastatic uveal melanoma (MUM), metastatic cutaneous melanoma, and neoadjuvant and adjuvant uveal melanoma (UM), *IDE397* – targeting MAT2A in MTAP-deletion tumors and *IDE161* – targeting PARG in solid tumors with HRD.

**Analyst Coverage** by BTIG, Capital One, Citi, Goldman Sachs, Jefferies, JP Morgan, Leerink, LifeSci Capital, Mizuho Securities, Oppenheimer, RBC, Stifel and Wedbush.

(1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), Amgen (IDE397 + AMG193), Gilead (IDE397 + Trodelyv®), and Merck (IDE161 + KEYTRUDA®); IDEAYA retains all commercial rights to its products

(2) GSK Collaboration, Option and License Agreement

(3) Includes aggregate of \$952.7M cash, cash equivalents and marketable securities as of June 30, 2024, plus pro forma \$283.8M estimated net proceeds from July 2024 public offering